Veru Inc. (NASDAQ:VERU) Given Average Rating of “Moderate Buy” by Analysts

Veru Inc. (NASDAQ:VERU) has been given an average recommendation of “Moderate Buy” by the five research firms that are currently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell rating and four have given a buy rating to the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $25.00.

VERU has been the topic of several analyst reports. Oppenheimer reiterated an “outperform” rating on shares of Veru in a research note on Thursday, December 18th. Canaccord Genuity Group initiated coverage on shares of Veru in a report on Thursday, December 18th. They issued a “buy” rating and a $25.00 price target on the stock. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Veru in a research report on Wednesday, October 8th. Finally, Wall Street Zen raised shares of Veru from a “sell” rating to a “hold” rating in a research report on Saturday, December 20th.

Veru Stock Down 0.4%

Veru stock opened at $2.31 on Friday. The business has a fifty day moving average of $2.78 and a two-hundred day moving average of $3.99. The firm has a market cap of $37.09 million, a P/E ratio of -1.05 and a beta of -1.01. Veru has a twelve month low of $2.11 and a twelve month high of $14.20.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Charles Schwab Investment Management Inc. raised its stake in Veru by 21.0% in the first quarter. Charles Schwab Investment Management Inc. now owns 375,291 shares of the company’s stock valued at $184,000 after buying an additional 65,045 shares during the last quarter. Nuveen LLC purchased a new position in shares of Veru in the 1st quarter valued at approximately $88,000. MPM Bioimpact LLC boosted its stake in Veru by 53.8% in the 1st quarter. MPM Bioimpact LLC now owns 6,592,727 shares of the company’s stock worth $3,231,000 after purchasing an additional 2,307,362 shares in the last quarter. Sender Co & Partners Inc. purchased a new stake in Veru during the 1st quarter worth approximately $64,000. Finally, SeaCrest Wealth Management LLC grew its position in Veru by 19.6% during the 2nd quarter. SeaCrest Wealth Management LLC now owns 165,000 shares of the company’s stock worth $96,000 after purchasing an additional 27,000 shares during the last quarter. 47.16% of the stock is currently owned by hedge funds and other institutional investors.

Veru Company Profile

Veru Inc is a clinical-stage biopharmaceutical company headquartered in Miami, Florida. The company is dedicated to the development and commercialization of novel therapies in the fields of oncology and infectious disease. Veru’s research strategy centers on advancing small-molecule and biologic candidates through clinical trials, leveraging its in-house manufacturing and formulation capabilities as well as strategic partnerships to support late-stage development.

The company’s lead product candidate is sabizabulin (VERU-111), an oral, microtubule-disrupting agent undergoing pivotal trials for indications that include metastatic castration-resistant prostate cancer and hospitalized patients with severe COVID-19.